Soliris Approval History
FDA Approved: Yes (First approved March 16, 2007)
Brand name: Soliris
Generic name: eculizumab
Dosage form: Injection
Company: Alexion Pharmaceuticals, Inc.
Treatment for: Paroxysmal Nocturnal Hemoglobinuria
Soliris is a complement inhibitor indicated for:
- the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis
- the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy
- the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.
Development History and FDA Approval Process for Soliris
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.